Lessons learned from recent lipid-lowering trials: Why physicians should change clinical practice

Anderson, 1987, Cholesterol and mortality: 30 years of follow-up from the Framingham study, JAMA, 257, 2176, 10.1001/jama.1987.03390160062027 Executive summary of the third report of the National Cholesterol Education Program (NCEP), 2001, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med., 333, 1301, 10.1056/NEJM199511163332001 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators, N Engl J Med., 355, 1001, 10.1056/NEJM199610033351401 Gotto, 2000, Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group, Am J Cardiol., 86, 1176, 10.1016/S0002-9149(00)01198-X 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 2002, MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial, Lancet, 360, 23, 10.1016/S0140-6736(02)09328-5 Hodges, 1973, Vitamin E and coronary heart disease, J Am Diet Assoc., 62, 638, 10.1016/S0002-8223(21)08997-5 Gey, 1990, The antioxidant hypothesis of cardiovascular disease: Epidemiology and mechanisms, Biochem Soc Trans., 18, 1041, 10.1042/bst0181041 Morris, 2003, Routine vitamin supplementation to prevent cardiovascular disease: A summary of the evidence for the U.S. Preventive Services Task Force, Ann Intern Med., 139, 56, 10.7326/0003-4819-139-1-200307010-00014 Marchioli, 2001, Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: Results of GISSI-Prevenzione trial. Gruppo Italiano per to Studio della Sopravvivenza nell'Infarto Miocardico, Lipids, 36, S119, 10.1007/s11745-001-0694-8 Yusuf, 2000, Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med., 342, 145, 10.1056/NEJM200001203420301 Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med., 345, 1583, 10.1056/NEJMoa011090 Kritchevsky, 1992, Serum cholesterol and cancer risk: An epidemiologic perspective, Annu Rev Nutr, 12, 391, 10.1146/annurev.nu.12.070192.002135 Law, 1994, Assessing possible hazards of reducing serum cholesterol, BMJ, 308, 373, 10.1136/bmj.308.6925.373 Simes, 1994, Low cholesterol and risk of non-coronary mortality, Aust N Z J Med., 24, 113, 10.1111/j.1445-5994.1994.tb04446.x Stamler, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022